JP2005506366A - 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤 - Google Patents

選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤 Download PDF

Info

Publication number
JP2005506366A
JP2005506366A JP2003537614A JP2003537614A JP2005506366A JP 2005506366 A JP2005506366 A JP 2005506366A JP 2003537614 A JP2003537614 A JP 2003537614A JP 2003537614 A JP2003537614 A JP 2003537614A JP 2005506366 A JP2005506366 A JP 2005506366A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
inhibitor
fluorine
methyl
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003537614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506366A5 (enExample
Inventor
イン−ナン・パン・チェン
ピーター・ラッソタ
アレキサンダー・ウォレス・ウッド
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2005506366A publication Critical patent/JP2005506366A/ja
Publication of JP2005506366A5 publication Critical patent/JP2005506366A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003537614A 2001-10-25 2002-10-24 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤 Pending JP2005506366A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (2)

Publication Number Publication Date
JP2005506366A true JP2005506366A (ja) 2005-03-03
JP2005506366A5 JP2005506366A5 (enExample) 2006-01-05

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003537614A Pending JP2005506366A (ja) 2001-10-25 2002-10-24 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤

Country Status (22)

Country Link
US (2) US20050043409A1 (enExample)
EP (1) EP1441714B1 (enExample)
JP (1) JP2005506366A (enExample)
KR (1) KR100954625B1 (enExample)
CN (1) CN100506224C (enExample)
AT (1) ATE381930T1 (enExample)
AU (2) AU2006252156A1 (enExample)
BR (1) BR0213486A (enExample)
CA (1) CA2464309C (enExample)
CY (1) CY1108045T1 (enExample)
DE (1) DE60224299T2 (enExample)
DK (1) DK1441714T3 (enExample)
ES (1) ES2295428T3 (enExample)
HU (1) HUP0600235A3 (enExample)
IL (1) IL161462A0 (enExample)
MX (1) MXPA04003878A (enExample)
NZ (2) NZ532418A (enExample)
PL (1) PL369305A1 (enExample)
PT (1) PT1441714E (enExample)
RU (1) RU2333754C2 (enExample)
SI (1) SI1441714T1 (enExample)
WO (1) WO2003035047A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091622A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
WO2005021554A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
MXPA06003164A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinaciones de un inhibidor del receptor de vegf con otros agentes terapeuticos.
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
CA2551508C (en) 2003-12-23 2011-08-09 Pfizer Inc. Novel quinoline derivatives
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN103917236A (zh) 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011605A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2001040216A1 (en) * 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
JP2001508800A (ja) * 1997-02-13 2001-07-03 ノバルティス アクチエンゲゼルシャフト 血管形成阻害活性を有するフタラジン
WO2001062252A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
WO2001072721A2 (en) * 2000-03-27 2001-10-04 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100558356C (zh) * 1996-10-15 2009-11-11 G.D.瑟尔公司 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
IL147913A0 (en) * 1999-08-12 2002-08-14 American Cyanamid Co Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
WO2001060365A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508800A (ja) * 1997-02-13 2001-07-03 ノバルティス アクチエンゲゼルシャフト 血管形成阻害活性を有するフタラジン
WO1999011605A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2001040216A1 (en) * 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
WO2001062252A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
WO2001072721A2 (en) * 2000-03-27 2001-10-04 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091622A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
JP2012255042A (ja) * 2006-02-09 2012-12-27 Daiichi Sankyo Co Ltd 抗癌医薬組成物
JP5133071B2 (ja) * 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物

Also Published As

Publication number Publication date
KR100954625B1 (ko) 2010-04-27
CA2464309C (en) 2012-01-03
AU2010200433A1 (en) 2010-02-25
PL369305A1 (en) 2005-04-18
CN100506224C (zh) 2009-07-01
US20050043409A1 (en) 2005-02-24
WO2003035047A2 (en) 2003-05-01
DK1441714T3 (da) 2008-03-31
BR0213486A (pt) 2005-05-10
NZ552335A (en) 2008-11-28
ATE381930T1 (de) 2008-01-15
EP1441714A2 (en) 2004-08-04
KR20040048992A (ko) 2004-06-10
SI1441714T1 (sl) 2008-06-30
EP1441714B1 (en) 2007-12-26
WO2003035047A3 (en) 2003-10-23
HK1068261A1 (en) 2005-04-29
HUP0600235A3 (en) 2008-04-28
RU2333754C2 (ru) 2008-09-20
DE60224299D1 (de) 2008-02-07
IL161462A0 (en) 2004-09-27
RU2004116069A (ru) 2005-06-10
ES2295428T3 (es) 2008-04-16
AU2006252156A1 (en) 2007-01-18
PT1441714E (pt) 2008-03-10
HUP0600235A2 (en) 2007-02-28
MXPA04003878A (es) 2004-07-08
NZ532418A (en) 2007-02-23
CN1575168A (zh) 2005-02-02
CY1108045T1 (el) 2013-09-04
US20110046190A1 (en) 2011-02-24
CA2464309A1 (en) 2003-05-01
DE60224299T2 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
US20110046190A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
US9421208B2 (en) Methods for the treatment of solid tumors
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
RU2660354C2 (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2016014890A1 (en) Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
US20230067378A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
CN119486713A (zh) 尼罗加司他治疗
AU2014207272A1 (en) Estrogen receptor inhibitors
CN114246864B (zh) Csf1r激酶抑制剂及其用途
JP2017521468A (ja) 組み合わせ療法
JP2025533719A (ja) がんの治療のためのｋａｔ６阻害剤を含む投与レジメン
CN117377492A (zh) 包含蛋白激酶抑制剂的药物组合物及其医药用途
CN116096367A (zh) Frs2–fgfr相互作用的小分子抑制剂及其在医学、在预防和治疗癌症中的用途
JP2023507387A (ja) インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
WO2020089190A2 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
US20230285347A1 (en) Preterm Labour with Prostaglandin E2 Receptor Agonists
AU2002351784A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
ZA200402939B (en) Combinations comprising a selective cyclooxygenase-2 inhibitor.
TW200950789A (en) Antitumor agent, kit and method of treating cancer
HK1068261B (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
US20030139430A1 (en) Use of organic compounds
WO2020061636A1 (en) Treatment of neuropathic pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907